Shots:

• The collaboration leverages Sorrento’s mAb against SARS-CoV-2 virus that will be encoded into a gene for delivery utilizing SmartPharm’s non-viral nanoparticle platform
• The companies are expected to develop a gene-encoded Abs that can be administered as prophylaxis against SARS-CoV-2 infection with the anticipated IND filing in the next few months
• SmartPharm’s Gene mAb platform acts by neutralizing the coronavirus with an ability to produce protective Ab directly in the muscle of the individual. The companies anticipate the novel approach will enable faster progression to a clinical- pending agreement with the FDA

Click here ­to­ read full press release/ article | Ref: Sorrento | Image:  Sorrento